- Home
- REVBW vs BME Comparison
REVBW vs BME Comparison
Compare REVBW & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- BME
- Stock Information
- Founded
- REVBW N/A
- BME 2005
- Country
- REVBW United States
- BME United States
- Employees
- REVBW 9
- BME N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- REVBW Health Care
- BME Finance
- Exchange
- REVBW Nasdaq
- BME Nasdaq
- Market Cap
- REVBW N/A
- BME 462.3M
- IPO Year
- REVBW 2020
- BME N/A
- Fundamental
- Price
- REVBW N/A
- BME $36.00
- Analyst Decision
- REVBW
- BME
- Analyst Count
- REVBW 0
- BME 0
- Target Price
- REVBW N/A
- BME N/A
- AVG Volume (30 Days)
- REVBW N/A
- BME 34.0K
- Earning Date
- REVBW N/A
- BME 01-01-0001
- Dividend Yield
- REVBW N/A
- BME 6.26%
- EPS Growth
- REVBW N/A
- BME N/A
- EPS
- REVBW N/A
- BME 1.44
- Revenue
- REVBW N/A
- BME N/A
- Revenue This Year
- REVBW N/A
- BME N/A
- Revenue Next Year
- REVBW N/A
- BME N/A
- P/E Ratio
- REVBW N/A
- BME $28.37
- Revenue Growth
- REVBW N/A
- BME N/A
- 52 Week Low
- REVBW N/A
- BME $35.53
- 52 Week High
- REVBW N/A
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- BME 39.05
- Support Level
- REVBW N/A
- BME $35.78
- Resistance Level
- REVBW N/A
- BME $36.65
- Average True Range (ATR)
- REVBW 0.00
- BME 1.11
- MACD
- REVBW 0.00
- BME -0.03
- Stochastic Oscillator
- REVBW 0.00
- BME 38.72
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.